"10.1371_journal.pone.0121915","plos one","2015-04-07T00:00:00Z","Bruce Wang; Joshua A Roth; Hiep Nguyen; Eugene Felber; Wes Furnback; Louis P Garrison","Elysia Group, LLC, New York, New York, United States of America; Department of Pharmacy, University of Washington, Seattle, Washington, United States of America; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; AstraZeneca, Fort Washington, Pennsylvania, United States of America; Bristol-Myers Squibb Company, New York, New York, United States of America","Conceived and designed the experiments: BW JR HN EF WF LG. Performed the experiments: BW JR HN WF LG. Analyzed the data: BW JR WF. Contributed reagents/materials/analysis tools: BW JR WF. Wrote the paper: BW JR HN EF WF LG.","BW, WF, JR, and LG are consultants for Bristol-Myers Squibb Company. HN is an employee of AstraZeneca. EF is an employee of Bristol-Myers Squibb Company. BW and WF are employees of Elysia Group, LLC. Exenatide is marketed by AstraZeneca. This study was funded by Bristol-Myers Squibb Company. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2015","04","Bruce Wang","BW",6,TRUE,6,5,3,6,TRUE,TRUE,FALSE,0,NA,FALSE
